Plus Therapeutics, Inc. announced its financial results for the second quarter ended June 30, 2025, on August 14, 2025. The company highlighted steady execution and progress on its key strategic initiatives, including the clinical development of its radiotherapeutic and the advancement of its diagnostic platform technologies.
New data announcements on the REYOBIQ™ CNS cancer radiotherapeutic clinical trials continue to demonstrate favorable safety and efficacy signals. This progress is facilitating active enrollment in the dose optimization trial for leptomeningeal metastases.
Furthermore, the company announced the launch of the CNSide® cerebral spinal fluid (CSF) assay platform and testing services in Texas, with an initial focus on national cancer centers. The company intends to expand its testing services and broaden the regional availability of CNSide over the next 12 months.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.